logo-loader

Respiri improves cash flow as it prepares for rollout of second-generation AirSonea

Published: 14:48 26 Feb 2018 AEDT

Respiratory measurement devices
Approvals for the new Air Sonea are expected to be in place by the end of year

Respiri Ltd (ASX:RSH) continued to better its cash flow position with a reduced first half loss of $782,909 compared with circa $1.8 million in the previous corresponding period.

The company is involved in the development of innovative devices and mobile health apps to improve the management of respiratory disorders such as asthma and COPD.

Respiri’s net cash outflow was $500,504 compared with circa $1.8 million in 2016.

While this reflects well on management from a financial perspective, the focus is likely to be on product development, market acceptance and rollout in 2018.

Breath sensor upgrade key priority

The development of a new breath sensor upgrade, the AirSonea Generation II is due for completion in the second quarter of 2018.

This will include a real-time smart app capability featuring the group’s proprietary acoustic respiratory monitoring algorithm with artificial intelligence or machine learning technology.

The company is confident of its success with this device having previously brought similar products to market in Europe and Australia.

In particular, the company’s wheeze detection technology has already established itself, having been incorporated in previous devices.

Plans to launch in Asia

The AirSonea Generation II will initially be targeted at Europe, Australia and the US, jurisdictions which have some of the most demanding regulatory authorities and processes.

Approval by these authorities will be beneficial in entering other markets, and management plans to launch the new device in select Asian markets.

Looking towards the latter part of 2018 and beyond, the company expects to have approvals in place by the end of year, with a view to increasing its portfolio of products in 2019.

Respiri to benefit from experienced management

Respiri enters 2018 with a strong leadership team having appointed former global Pfizer Inc. (NYSE:PFE) executive Mario Gattino as chief executive officer in December.

He brings over 25 years’ experience in senior leadership positions within the medical industry, having successfully commercialised drugs and medical devices globally.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

8 hours, 30 minutes ago